Moditope®
Moditope® is a unique class of potent, off the shelf peptide vaccine targeting posttranslational modifications expressed by a wide range of tumours.
Modi-1, is the first therapeutic vaccine candidate to emerge from Company’s Moditope® platform
Modi-1 targets citrullinated peptides, tumour-specific neoantigens generated from stress-induced post translational modifications (siPTMs). Peptides from two different proteins have been combined in this way to reduce the possibility of tumour escape. Currently, Modi-1 has completed dose escalation and safety cohorts of the Phase 1/2 ModiFY trial and continues in the expansion cohorts. Early data from patients receiving Modi-1 as a monotherapy, has shown prolonged periods of stable disease, with no dose limiting toxicities observed in dose escalation cohorts.
Tumour-specific neoantigens. Modi-1 targets citrullinated peptides, tumour-specific neoantigens generated from stress-induced post translational modifications (siPTMs) via the MHC-II presentation pathway.
siPTMs occur in all cancer cells. Citrullination occurs as a result of autophagy induced in stressed cancer cells. Citrullination protects from proteolytic cleavage and creates neo-epitopes.
Robust GMP manufacturing process, stable shelf life and faster route to treatment allowing pricing flexibility. Five-year stability.
Favourable safety profile and well tolerated when administered as a monotherapy and in combination with checkpoint inhibitors.
MODI-2 Targets siPTMs such as homocittrullination. Groundbreaking science with strong patent position offering off the shelf pan-cancer vaccine targeting neoantigens in cancer.
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.
